Mucosolvan Max (Ambroxol Hydrochloride)

Ambroxol, the active ingredient in Mucosolvan Max, is a mucolytic agent presented as an oral formulation for oral use. It helps to reduce mucus viscosity and improve clearance in patients with respiratory conditions that produce thickened secretions. GNH USA supplies Mucosolvan Max as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mucosolvan Max is a mucolytic that acts on the respiratory tract to facilitate mucus clearance in several pulmonary conditions.

Acute bronchitis: loosens thick mucus, aiding expectoration. Chronic bronchitis: reduces mucus viscosity, improving cough efficiency. Chronic obstructive pulmonary disease (COPD): enhances mucociliary transport, easing breathing. Asthma with productive cough: assists in clearing airway secretions. Other respiratory conditions with thickened mucus: supports overall airway hygiene.

Ambroxol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea - Taste disturbance (bitter taste) - Abdominal discomfort - Headache - Diarrhea - Mild skin rash

Serious or Rare Side Effects: - Allergic reactions (urticaria, pruritus) - Severe skin reactions (Stevens‑Johnson syndrome) - Eosinophilia - Hepatic enzyme elevation - Angioedema - Anaphylactic shock

Use ambroxol with consideration of patient-specific factors and potential risks.

Assess renal function: adjust use in severe impairment. Monitor for hypersensitivity: discontinue if allergic reactions develop. Use with caution in asthma: ensure underlying inflammation is controlled. Avoid in patients with known hypersensitivity to ambroxol or related compounds. Pregnancy and lactation: consult a physician before use. Store at ambient temperature: keep in the original pack, protect from moisture.

Ambroxol may interact with other medications, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent use with codeine‑containing antitussives: may diminish mucolytic effect. - Combination with other mucolytics (e.g., N‑acetylcysteine): risk of excessive mucus thinning. - Strong CYP2D6 inhibitors: may increase ambroxol plasma concentrations.

Moderate Interactions (Monitor Closely): - Bronchodilators (e.g., salbutamol): monitor respiratory response. - Antihistamines: possible increase in sedation. - Alcohol: may exacerbate gastrointestinal irritation.